A drug reimportation bill that would enable consumers, drug retailers, and wholesalers to import cheaper foreign drugs from FDA-approved plants and warehouses continues to gain support. The CBO reported that the bill would generate $50 billion in savings for pharmaceutical purchasers over 10 years.
While a floor vote has not yet been scheduled in either house, we continue to believe this, or a similar drug reimportation bill, will pass both houses in this Congress.
The real question is can its supporters sustain a Bush veto? That one is too close to call.
A Health Care Reform Blog––Bob Laszewski's review of the latest developments in federal health policy, health care reform, and marketplace activities in the health care financing business.
Subscribe
Avoid having to check back.
Subscribe to Health Care Policy and Marketplace Review and receive an email each time we post.
Blog Archive
-
▼
2007
(235)
-
▼
April
(17)
- The Carnival of Risk # 24 is Up
- Humana Caps Annual Increases on Consumer-Driven Pl...
- The Medicare Fee-For-Service Product is a Kamikaze...
- Medicare Drug Negotiation Bill Fails in the Senate
- Latest "Health Wonk Review" is Up
- Hillary Clinton Doesn't Like Health Insurance Comp...
- Democratic Presidential Candidate Bill Richardson ...
- The Imus Fiasco and the Virginia Tech Massacre—Wha...
- Senate Developments on Medicare Advantage Payments...
- More Than 10 Million Are Now Using Consumer-Driven...
- Another Victory Declared in Massachusetts--The Con...
- The Medicare Part D Drug Benefit: "The Ugliest Nig...
- A Bipartisan Bill to Ban Genetic Discrimination Co...
- A Drug Reimportation Bill Continues to Receive Bip...
- A Mental Health Parity Bill Still on Track for Pas...
- The Health Wonk Review--A New and Improved U.S. He...
- The Real Reason Health Care Reform is Hard—Hillary...
-
▼
April
(17)